Flow Sciences Appoints Michael Gesser as CFO

Why It Matters

The hire brings seasoned financial expertise to guide Flow Sciences’ scaling operations and capital structure as it deepens its presence in the high‑growth RTP biotech hub.

Key Takeaways

• Michael Gesser appointed CFO, also remains board member.
• Gesser brings 30+ years finance experience in life sciences.
• Previously CFO at Acorda, Osmotica, Tergus, BioMedomics, SunTech.
• Will oversee finance, accounting, tax, treasury, FP&A, investor relations.
• Supports expansion of RTP hub and containment solutions portfolio.

Pulse Analysis

Flow Sciences, a provider of containment solutions for hazardous materials, has been accelerating its footprint in the United States, most notably with the opening of a state‑of‑the‑art facility in North Carolina’s Research Triangle Park (RTP) in 2025. The RTP location serves as a showroom, training center, and design hub for pharmaceutical and biotechnology clients, positioning the company near a dense cluster of life‑science innovators. As the firm scales its product portfolio and pursues larger contracts, a seasoned finance leader is essential to steer budgeting, capital allocation, and compliance across a rapidly expanding operation.

Michael Gesser steps into the CFO role after more than 30 years of financial stewardship in publicly traded and privately held life‑science enterprises. His résumé includes CFO tenures at Acorda Therapeutics, Osmotica Pharmaceutical, Tergus Pharma, BioMedomics and SunTech Medical, where he oversaw complex regulatory reporting, R&D financing, and M&A activity. Gesser’s deep familiarity with the nuances of pharma and medical‑device cash flows equips him to optimize Flow Sciences’ balance sheet, manage treasury risk, and enhance investor‑relations at a time when capital markets are scrutinizing biotech‑adjacent services.

The appointment signals to investors that Flow Sciences is prioritizing financial discipline while pursuing aggressive growth in the RTP ecosystem. Gesser’s board experience with the company means he already understands its strategic roadmap, allowing for a seamless transition to executive responsibilities. By tightening financial planning and expanding the company’s capital structure, Flow Sciences can accelerate product development, broaden its containment solutions, and capture a larger share of the burgeoning demand for safe handling of biologics and gene‑therapy materials. The move underscores the broader trend of niche service providers bolstering leadership to meet the biotech boom.